Relative Lack of Systemic Effects of Mometasone Furoate on Langerhans Cells of Mice After Topical Administration as Compared with Other Glucocorticosteroids

• Published in: Journal of investigative dermatology Vol. 91; no. 3; pp. 219 - 223
• Main Authors: Belsito, Donald V., Baer, Rudolf L., Schultz, Jan M., Thorbecke, G Jeanette
• Format: Journal Article
• Language: English
• Published: Danvers, MA Elsevier Inc 01.09.1988; Nature Publishing
• Subjects: Administration, Topical; Animals; Biological and medical sciences; Corticoids; Dermatology; Ear - drug effects; Ear - pathology; Female; Glucocorticoids - administration & dosage; Glucocorticoids - pharmacology; Histocompatibility Antigens Class II - analysis; Hormones. Endocrine system; Langerhans cells; Langerhans Cells - drug effects; Langerhans Cells - immunology; Medical sciences; Mice; Mice, Inbred BALB C; Mometasone Furoate; Pharmacology. Drug treatments; Pregnadienediols - administration & dosage; Pregnadienediols - pharmacology; Steroid hormones; Topical application; Local administration; Vertebrata; Mammalia; Langerhans cell; Mouse; Animal; Rodentia; Glucocorticoid; Comparative study
• ISSN: 0022-202X; 1523-1747
• DOI: 10.1111/1523-1747.ep12465012

The effects of topically applied mometasone furoate were compared with those of other glucocorticosteroids, in particular fluocinolone acetonide, in assays of murine epidermal Ia+ Langerhans cell density. No evidence of systemic effects, as determined by a decline in the density of Ia+ LC in distant sites, was detected after local topical applications (5 times a week) of mometasone furoate 0.001% for periods of up to 3 weeks. Other steroids, even in such very low concentrations, and mometasone furoate in higher concentrations, produced systemic effects on Ia+ LC when used for longer than 5d. The recovery time of Ia+ Langerhans cells is significantly shorter after application of mometasone furoate than after fluocinolone acetonide. However, with both compounds, recovery occurred more rapidly after 3 weeks than after a 1- or 2-week interval of compound administration.